Pakistan Institute of Medical Sciences, Islamabad

CHILDREN’S HOSPITAL · PIMS

Thalassemia Center

CHILDREN’S HOSPITAL

Overview

The centre deals with the screening, diagnosis, treatment and management of patients with thalassemia syndromes, hemophilia and platelet disorders.

Prof. Dr. Nuzhat Yasmeen
Head of Department, Pediatric Medicine and Pediatric Hematology Oncology, Children’s Hospital, PIMS.

Centre in charge: Dr. Tazeen Anwar, Thalassemia Center, Children’s Hospital, PIMS.

Services

  • Transfusion of packed red cells (RCC) and other blood products to patients.
  • Management of patients with hypersensitivity reactions during and after the reaction.
  • Intravenous (IV) or subcutaneous (SC) chelation therapy for patients with thalassemia.
  • Referral of patients to wards when they are sick or require ward-based management, including splenectomy, target joint problems and intracranial bleeding.
  • Provision of Factor VIII/IX, to required patients, arranged through the Hemophilia Society.

Facilities

  • One ward operating 12 hours daily.
  • One OPD operating 12 hours daily.
  • 16–18 beds/couches.

Faculty & key staff

Dr. Tazeen Anwar

Senior Medical Officer, CH, PIMS; In charge, Thalassemia Center

MBBS, RMP, DCH and MCPS (Training)

Dr. Abdur Riaz

Senior Medical Officer, CH, PIMS

MBBS, RMP

Dr. Ameer Bacha Khan

Medical Officer, CH, PIMS

MBBS, RMP

OPD & patient information

  • OPD: Monday to Saturday
  • OPD timings: 8:00 AM to 8:00 PM.
  • Patient registration: 8:00 AM to 2:00 PM.
  • Referral is made when required, including when a patient is sick or is a candidate for bone marrow transplantation (BMT) or splenectomy, if needed.

Location

Ground floor, Children’s Hospital (CH), opposite the office of the Head of Department of Pediatric Medicine.

Additional information

  • Introduction of leucoreduced filters in order to decrease the incidence of hypersensitivity reactions.
  • Various research activities have been completed, and some are ongoing.
  • Screening for hepatitis B, hepatitis C and HIV in chronic blood and blood product transfusion patients.